.gif)
Zydus group has entered into an in-licensing agreement with Neovii, a Switzerland based global biopharmaceutical company to launch Grafalon, an immunosuppresant extensively used in solid organ transplants and stem cell transplant, in India. Neovii has been dedicated for over three decades to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders.
Innovus Pharmaceuticals, Inc. (Innovus Pharma), an emerging commercial stage pharmaceutical company, has initiated a pre-clinical and clinical programme intended to evaluate the safety and efficacy of the combination of its supplement Vesele for promoting sexual health with sildenafil indicated for treating erectile dysfunction. Sildenafil in the US is sold under the name Viagra by Pfizer, Inc. (Pfizer).
Amgen announced that new data on Imlygic (talimogene laherparepvec) in combination with an immune checkpoint inhibitor and results from retrospective analyses on Vectibix (panitumumab) will be presented at the European Society for Medical Oncology (ESMO) 2016 Congress, October 7-11, 2016, in Copenhagen.
Eisai Co., Ltd. announced that its U.S. subsidiary Eisai Inc. has launched BELVIQ XR® 20mg tablets, a new once-daily formulation of BELVIQ® (generic name: lorcaserin hydrochloride) for chronic weight management in the United States.
BELVIQ XR is an extended release formulation proven to be slowly absorbed in the body and to last throughout the day. The availability of once-daily BELVIQ XR (20mg) in a single tablet provides patients with another dosing option in addition to the conventional twice-daily BELVIQ (10mg).
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
